Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03410693
Recruitment Status : Active, not recruiting
First Posted : January 25, 2018
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Bayer

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 25, 2022
  Estimated Study Completion Date : April 25, 2022